Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 88.21
Day High 89.92
Open:89.45
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Keloid Treatment Market Report Growth During by 2024
- Heraldkeepers - Fri Aug 23, 11:58AM CDT
Heraldkeepers - CMTX
Fri Aug 23, 11:58AM CDT
Global is segmented based on the treatments type as, Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Radiation Therapy, Laser Therapy, Interferon Therapy, Intralesional Corticosteroid Injection and Others. The report segments global Keloid Treatment Market based on end-use as Hospitals, Dermatology Clinics, Ambulatory Surgical Centres and Others.
Pain Management Therapeutics Market is Likely to Clock a CAGR of 4.0%, Booming Healthcare Industry to Create a Positive Growth Environment Globally - TMR
- PR Newswire - Fri Aug 23, 5:35AM CDT
PR Newswire - CMTX
Fri Aug 23, 5:35AM CDT
Advanced health care and medication are now into the main stream along with large number of players participating in it. This factor has also lead the demand in the global pain management therapeutics market. Players in this market are witnessing high growth due to the increased demand for therapeutics for pain management. Leading players are engaged in research and developments and they are investing heavily in partnership, collaboration, and innovation that will help them in making their strong presence in the market. Currently, with large number of players participating in the market, the global pain management therapeutics market has a fragmented vendor landscape. Competition in the market is also expected to rise in the near future due to various efforts made by these players. In the Transparency Market Research report on the global pain management therapeutics market, analysts have thoroughly analyzed key players holding significant share in the market. To name a few leading players presented in the report includes Novartis AG, Endo Health Solutions, Inc., Abbott Laboratories, Pfizer, Inc., Merck & Co. Inc., F. Hoffmann La Roche Ltd., Johnson & Johnson, and Purdue Pharma L.P.
Former Novartis CEO and Eli Lilly's Drug Development Leader are Featured Keynote Speakers at Veeva R&D Summit
- BusinessWire - Thu Aug 22, 12:00PM CDT
BusinessWire - CMTX
Thu Aug 22, 12:00PM CDT
Veeva Systems (NYSE:VEEV) today announced that Joe Jimenez, former CEO of Novartis, and Rob Metcalf, vice president of medicines development at Eli Lilly and Company, are featured keynote speakers at the 2019 Veeva R&D Summit. As visionaries at the forefront of breakthrough treatments in life sciences, they will discuss opportunities to speed product development throughout the industry.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 86.74 +1.96% increase
on 08/06/19
Period Open:93.68
Price movement based on the high, low and last over the given period.
93.34 -5.25% decrease
on 07/24/19
-5.24 (-5.59%) decrease
since 07/23/19
3-Month 85.33 +3.64% increase
on 05/31/19
Period Open:84.44
Price movement based on the high, low and last over the given period.
95.00 -6.91% decrease
on 07/18/19
+4.00 (+4.74%) increase
since 05/23/19
52-Week 71.40 +23.87% increase
on 09/06/18
Period Open:73.55
Price movement based on the high, low and last over the given period.
95.00 -6.91% decrease
on 07/18/19
+14.89 (+20.25%) increase
since 08/23/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).